Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1059MR)

This product GTTS-WQ1059MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1059MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15397MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ3295MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ4146MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ8445MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ3374MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ594MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ5067MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ11878MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-0264
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW